文献库搜索 | GeneLibs

Ector(C),Schmal(C),Didier(J),De Landtsheer... Cell Rep 2026-02-24

...ALK inhibitor lorlatinib and frontline chemotherapeutics revealed distinct temporal drug responses that were more pronou...

Hong(D),Kwon(HJ),Jeong(J),Yoon(S),Chung(JH... Mol Cells 2026-04-00

...ALK) gene rearrangements represent key oncogenic drivers, and ALK tyrosine kinase inhibitors such as crizotinib have sig...

Wang(S),He(P),Liang(Y),Zhang(X),Yan(Y),Yua... Environ Res 2026-04-01

...alkylated PAHs (Alk-PAHs), oxygenated PAHs (OPAHs), and heterocyclic aromatic hydrocarbons (HAHs), were quantified in 19...

Koutoukoglou(P),Mountzios(G) Cancers (Basel) 2026-02-02

...ALK inhibitor alectinib in patients with an ALK fusion/translocation has brought about a paradigm shift by significantly...

Özdemir(M),Gököz Doğu(G),Yapar Taşköylü(B)... Cancers (Basel) 2026-02-03

...ALK-positive and 91 ALK-negative metastatic NSCLC patients were retrospectively analyzed. Systemic markers, including HA...

De Bona(A),Barbieri(M),Rinaldi(N),Esposito(S) J Clin Med 2026-01-30

...ALK mutations, and chromosomal aberrations-in disease behavior and prognosis. Contemporary risk stratification systems n...

Fu(Z),Huang(G),Xie(J),Luo(L),Ren(Q),He(H),... Front Oncol None

...ALK, or ROS1 alterations. We report an advanced SMARCA4-dNSCLC case with brain metastasis exhibiting a novel CTNND2-ALK/...

Alder(L),Mullikin(TC),Lascola(C),Sperduto(PW) Lung Cancer 2026-04-00

...ALK, PD-L1 for NSCLC). The GPA-based Eligibility Quotient (EQ) uses conditional probability to determine trial eligibili...

Cohen(T),Zhou(T),Edema(U),Pandit-Taskar(N)... NPJ Precis Oncol 2026-02-14

...ALK) negative subtype. Despite frontline treatment advances, there is no standard approach to treat relapsed disease and...

Mittelman(L),Vargas(LO),Abikenari(M),Latzm... J Clin Neurosci 2026-05-00

...alk, dormancy, immune evasion, and resistance genetics. Foundational pre-1990 works were included when biologically esse...